Sarepta Therapeutics, Inc.
22.02USD
+1.0800 (+5.16%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.42▼ | $0.5 | 4 | 5 |
| Next quarter | $0.17▼ | $0.44 | 2 | 7 |
| Current year | $4.44▼ | $4.83 | 4 | 7 |
| Next year | $2.57▼ | $2.73 | 6 | 5 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.49 | $0.64 | +0.15 (+31.7%) |
| 2026-03-31 | $1.05 | $3.16 | +2.11 (+202.1%) |
| 2025-12-31 | $-0.77 | $-3.58 | -2.81 (-365.3%) |
| 2025-09-30 | $-0.37 | $-0.13 | +0.24 (+65.0%) |
493 ratings from 47 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Piper Sandler | Maintained | Neutral | $23 $20 | Jul 9, 2026 |
| Wolfe Research | Upgraded from Peer Perform | Outperform | $27 | Jul 9, 2026 |
| HC Wainwright & Co. | Reiterated | Sell | $5 | Apr 16, 2026 |
| Citigroup | Maintained | Sell | $9 $13 | Mar 26, 2026 |
| Needham | Reiterated | Underperform | — | Mar 26, 2026 |
| Oppenheimer | Reiterated | Outperform | $37 | Mar 19, 2026 |
| Mizuho | Maintained | Outperform | $26 $31 | Mar 13, 2026 |
| Citigroup | Maintained | Sell | $8 $9 | Mar 10, 2026 |
| HC Wainwright & Co. | Reiterated | Sell | $5 | Mar 2, 2026 |
| Wells Fargo | Maintained | Overweight | $45 $38 | Feb 27, 2026 |
| HC Wainwright & Co. | Reiterated | Sell | $5 | Jan 27, 2026 |
| Wedbush | Maintained | Outperform | $32 $34 | Jan 23, 2026 |
| HC Wainwright & Co. | Reiterated | Sell | $5 | Jan 14, 2026 |
| Wedbush | Initiated | Outperform | $32 | Dec 9, 2025 |
| Barclays | Maintained | Equal-Weight | $22 $20 | Nov 5, 2025 |
| Wells Fargo | Maintained | Overweight | $50 $45 | Nov 5, 2025 |
| Guggenheim | Maintained | Buy | $22 $19 | Nov 5, 2025 |
| Mizuho | Upgraded from Neutral | Outperform | $19 $26 | Nov 5, 2025 |
| Baird | Maintained | Neutral | $21 $15 | Nov 4, 2025 |
| Piper Sandler | Maintained | Neutral | $15 $16 | Oct 30, 2025 |
| BMO Capital | Upgraded from Market Perform | Outperform | $50 | Sep 22, 2025 |
| Guggenheim | Reiterated | Buy | $22 | Sep 15, 2025 |
| Leerink Partners | Maintained | Market Perform | $12 $15 | Sep 9, 2025 |
| HC Wainwright & Co. | Reiterated | Sell | $5 | Aug 25, 2025 |
| B of A Securities | Maintained | Underperform | $17 $16 | Aug 21, 2025 |
58 filings from 20 insiders · 9 buy / 1 sell over 6m
Officers and directors of SRPT, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wong Ryan Ho-YanOfficer, Chief Financial Officer | Tax | 13.3k | $22.22 | $295k | Sep 4, 2026 |
| Estepan Ian MichaelOfficer, Chief Operating Officer | Tax | 24.8k | $22.22 | $551k | Sep 4, 2026 |
| Rothfuss CristinOfficer, EVP, General Counsel | Tax | 22.0k | $22.22 | $489k | Sep 4, 2026 |
| Rodino-Klapac LouiseOfficer, President, R&D and Tech Ops | Tax | 21.4k | $22.22 | $476k | Sep 4, 2026 |
| SEVERINO MICHAEL EChief Executive Officer | Grant | 756.1k | — | — | Jul 28, 2026 |
| BEHRENS M KATHLEENDirector | Grant | 16.9k | — | — | Jun 4, 2026 |
| CHAMBERS MICHAEL ANDREWDirector | Grant | 16.9k | — | — | Jun 4, 2026 |
| WIGZELL HANS LENNART RUDOLFDirector | Grant | 16.9k | — | — | Jun 4, 2026 |
| CONNELLY DEIRDRE PDirector | Grant | 16.9k | — | — | Jun 4, 2026 |
| BARRY RICHARD JDirector | Grant | 16.9k | — | — | Jun 4, 2026 |
| NICAISE CLAUDEDirector | Grant | 16.9k | — | — | Jun 4, 2026 |
| BOOR KATHRYN JEANDirector | Grant | 16.9k | — | — | Jun 4, 2026 |
| MAYO STEPHEN L.Director | Grant | 16.9k | — | — | Jun 4, 2026 |
| MAYO STEPHEN L.Director | Sell | 7.2k | $17.02 | $123k | Mar 12, 2026 |
| RODINO-KLAPAC LOUISEOfficer | Other | 8.1k | — | — | Feb 27, 2026 |
| ESTEPAN IAN MICHAELChief Operating Officer | Other | 8.1k | — | — | Feb 27, 2026 |
| ESTEPAN IAN MICHAELChief Operating Officer | Exercise | 7.5k | $13.71 | $102k | Feb 26, 2026 |
| NICAISE CLAUDEDirector | Exercise | 10.5k | $13.71 | $144k | Jan 29, 2026 |
| BEHRENS M KATHLEENDirector | Exercise | 10.5k | $13.71 | $144k | Jan 27, 2026 |
| ESTEPAN IAN MICHAELChief Operating Officer | Sell | 13.2k | $22.31 | $294k | Dec 16, 2025 |
No analyst notes on SRPT yet.
Analyst Ratings
23 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 8 | 11 | 3 | 2 | Hold2.96 |
| 1 mo ago | 0 | 8 | 11 | 3 | 2 | Hold2.96 |
| 2 mo ago | 0 | 8 | 11 | 3 | 2 | Hold2.96 |
| 3 mo ago | 0 | 7 | 13 | 3 | 2 | Hold3.00 |